Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | RXRB | P28702 | 1/20 | 0.59 |
| ▸ | RXRG | P48443 | 1/20 | 0.59 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29682135 | 0.84 | L3MBTL1 (0.80) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL340762 | 0.84 | L3MBTL1 (0.80) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| Ammonia Solution, Strong SCHEMBL28240461 | 0.82 | L3MBTL1 (0.77) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL12840659 | 0.82 | L3MBTL1 (0.61) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL19406532 | 0.81 | ALDH1A1 (0.57) | L3MBTL1POLBSMN1; SMN2GLARXRA | |
| SCHEMBL1508470 | 0.80 | RXRA (0.42) | L3MBTL1POLBSMN1; SMN2GLARXRA | |
| SCHEMBL4577451 | 0.80 | PTGDR2 (0.56) | POLBSMN1; SMN2PTGDR2FFAR4PKM | |
| SCHEMBL15551585 | 0.79 | USP2 (0.55) | L3MBTL1POLBSMN1; SMN2GLARXRA | |
| SCHEMBL22434874 | 0.79 | PTGDR2 (0.55) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 | |
| SCHEMBL8115884 | 0.79 | L3MBTL1 (0.71) | L3MBTL1POLBSMN1; SMN2GLAPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-04-26 | — | — | US | disclosed |
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2289868-A1 | CARBOXYLIC ACID COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2011-03-02 | — | — | EP | disclosed |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | KOWA CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| US-6613942-B1 | Nonpeptide; 4-hydroxy benzoic acid hydrazides | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-0994848-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053974-A1 | CARBOXYLIC ACID COMPOUND | AKR1C3, SLC5A1, GPR119 | L3MBTL1 2338/4885POLB 4173/4885SMN1; SMN2 3695/4885 |
| US-20120101105-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | L3MBTL1 3988/4885POLB 4542/4885SMN1; SMN2 700/4885 |
| US-20080306102-A1 | NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME | HSD11B1, HSD11B2, HSD3B1 | L3MBTL1 3983/4885POLB 3897/4885SMN1; SMN2 4428/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | L3MBTL1 3977/4885POLB 4531/4885SMN1; SMN2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.